JP4171656B2 - Ｎ−（アリール）−２−アリールエテンスルホンアミド及びその製薬用途 - Google Patents

Ｎ−（アリール）−２−アリールエテンスルホンアミド及びその製薬用途 Download PDF

Info

Publication number
JP4171656B2
JP4171656B2 JP2002567237A JP2002567237A JP4171656B2 JP 4171656 B2 JP4171656 B2 JP 4171656B2 JP 2002567237 A JP2002567237 A JP 2002567237A JP 2002567237 A JP2002567237 A JP 2002567237A JP 4171656 B2 JP4171656 B2 JP 4171656B2
Authority
JP
Japan
Prior art keywords
aryl
cells
radiation
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002567237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004530655A5 (https=
JP2004530655A (ja
Inventor
レディー イー．プレムクマル
レディー エム．ヴィ．ラマナ
シー．ベル スタンリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple Univ School of Medicine
Original Assignee
Temple Univ School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple Univ School of Medicine filed Critical Temple Univ School of Medicine
Publication of JP2004530655A publication Critical patent/JP2004530655A/ja
Publication of JP2004530655A5 publication Critical patent/JP2004530655A5/ja
Application granted granted Critical
Publication of JP4171656B2 publication Critical patent/JP4171656B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/23—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/27—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2002567237A 2001-02-28 2002-02-28 Ｎ−（アリール）−２−アリールエテンスルホンアミド及びその製薬用途 Expired - Fee Related JP4171656B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27198501P 2001-02-28 2001-02-28
PCT/US2002/005979 WO2002067865A2 (en) 2001-02-28 2002-02-28 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof

Publications (3)

Publication Number Publication Date
JP2004530655A JP2004530655A (ja) 2004-10-07
JP2004530655A5 JP2004530655A5 (https=) 2006-01-05
JP4171656B2 true JP4171656B2 (ja) 2008-10-22

Family

ID=23037924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002567237A Expired - Fee Related JP4171656B2 (ja) 2001-02-28 2002-02-28 Ｎ−（アリール）−２−アリールエテンスルホンアミド及びその製薬用途

Country Status (11)

Country Link
US (1) US6646009B2 (https=)
EP (1) EP1379508B9 (https=)
JP (1) JP4171656B2 (https=)
KR (1) KR100850330B1 (https=)
AT (1) ATE479657T1 (https=)
AU (1) AU2002306604B2 (https=)
CA (1) CA2439255C (https=)
DE (1) DE60237512D1 (https=)
DK (1) DK1379508T3 (https=)
IL (2) IL157540A0 (https=)
WO (1) WO2002067865A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002069892A2 (en) * 2001-02-28 2002-09-12 Temple University Of The Commonwealth System Of Higher Education METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES
NZ535232A (en) * 2002-02-28 2007-05-31 Univ Temple Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
EP1534284B1 (en) * 2002-02-28 2011-07-27 Temple University - Of The Commonwealth System of Higher Education Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
WO2005046599A2 (en) * 2003-11-14 2005-05-26 Temple University - Of The Commonwealth System Of Higher Education Alpha, beta-unsaturated sulfoxides for treating proliferative disorders
NZ549962A (en) 2004-03-16 2010-04-30 Univ Temple Substituted phenoxy-and phenylthio-derivatives for treating proliferative disorders
WO2005090297A1 (en) * 2004-03-19 2005-09-29 Biotie Therapies Corporation Sulphonamide derivatives
DK2035369T3 (da) * 2006-07-05 2014-10-06 Fibrotech Therapeutics Pty Ltd Terapeutiske
JP5278968B2 (ja) 2006-08-30 2013-09-04 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 骨髄異形性症候群及び急性骨髄性白血病の治療のための組成物及び方法
WO2009079692A1 (en) * 2007-12-21 2009-07-02 Fibrotech Therapeutics Pty Ltd Halogenated analogues of anti-fibrotic agents
WO2010144959A1 (en) * 2009-06-18 2010-12-23 Fibrotech Therapeutics Pty Ltd Analogues of anti-fibrotic agents
EP2491030B1 (en) 2009-10-22 2015-07-15 Fibrotech Therapeutics PTY LTD Fused ring analogues of anti-fibrotic agents
WO2013039985A2 (en) * 2011-09-12 2013-03-21 The Johns Hopkins University Serine protease inhibitors
WO2013056079A1 (en) * 2011-10-13 2013-04-18 The Johns Hopkins University High affinity beta lactamase inhibitors
AU2013318206B2 (en) 2012-09-20 2018-07-26 Temple University - Of The Commonwealth System Of Higher Education Substituted alkyl diaryl derivatives, methods of preparation and uses
US10383831B2 (en) 2015-08-03 2019-08-20 Temple University—Of the Commonwealth System of Higher Education 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use
CA3052036A1 (en) 2017-02-03 2018-08-09 Certa Therapeutics Pty Ltd. Anti-fibrotic compounds
MA54753A (fr) * 2019-01-17 2021-11-24 Ifm Due Inc Composés et compositions pour traiter des états pathologiques associés à une activité de sting
UY39892A (es) 2021-08-10 2023-03-31 Novartis Pharma Ag Compuestos y composiciones para tratar afecciones asociadas con la actividad de STING

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2531367A (en) * 1947-07-15 1950-11-21 Sharp & Dohme Inc N-(substituted sulfonyl)-aminobenzoic acids
DE2118493C3 (de) 1971-04-16 1980-04-30 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Aminostilbenen
US4035421A (en) 1976-03-19 1977-07-12 Morton-Norwich Products, Inc. N-(3,4,-dichlorophenyl)-2-phenylethenesulfonamide
DE2809377A1 (de) * 1978-03-04 1979-09-13 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeure-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
IL98784A0 (en) 1990-07-17 1992-07-15 Lilly Co Eli Heterocyclyl sulfonamide derivatives,process for their preparation and pharmaceutical compositions containing them
JPH04202173A (ja) * 1990-11-30 1992-07-22 Zeria Pharmaceut Co Ltd スルホンアミド誘導体及びそれを含有する５―リポキシゲナーゼ阻害剤
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
EP0809492A4 (en) 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
DE69724777T2 (de) 1996-02-22 2004-07-15 Tularik, Inc., South San Francisco Pentafluorobenzensulfonamiden und analoge
US6191170B1 (en) * 1998-01-13 2001-02-20 Tularik Inc. Benzenesulfonamides and benzamides as therapeutic agents
ES2194547T3 (es) 1998-09-23 2003-11-16 Tularik Inc Arilsulfonanilida-ureas.
US6586617B1 (en) * 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives

Also Published As

Publication number Publication date
DE60237512D1 (de) 2010-10-14
KR20030086279A (ko) 2003-11-07
AU2002306604B2 (en) 2007-09-13
CA2439255C (en) 2011-01-04
IL157540A (en) 2010-11-30
EP1379508B9 (en) 2011-02-09
IL157540A0 (en) 2004-03-28
US6646009B2 (en) 2003-11-11
EP1379508A2 (en) 2004-01-14
JP2004530655A (ja) 2004-10-07
KR100850330B1 (ko) 2008-08-04
WO2002067865A2 (en) 2002-09-06
WO2002067865A3 (en) 2003-03-20
DK1379508T3 (da) 2011-01-03
CA2439255A1 (en) 2002-09-06
US20020165412A1 (en) 2002-11-07
EP1379508A4 (en) 2005-12-28
EP1379508B1 (en) 2010-09-01
ATE479657T1 (de) 2010-09-15

Similar Documents

Publication Publication Date Title
JP4171656B2 (ja) Ｎ−（アリール）−２−アリールエテンスルホンアミド及びその製薬用途
JP4302986B2 (ja) 細胞及び組織をα，β不飽和アリールスルホンにより電離放射線から防護する方法
AU2002305942A1 (en) Method for protecting cells and tissues from ionizing radiation toxicity with Alpha, Beta unsaturated aryl sulfones
AU2002306604A1 (en) N-(Aryl)-2-arylethenesulfonamides and therapeutic uses thereof
EP1539675B1 (en) Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof
IL143709A (en) Use of androgen receptor suppressors
CN104010501A (zh) 含src同源区2蛋白酪胺酸磷酸酶-1增效剂及其治疗方法
WO2020131998A1 (en) Notch inhibitors for the treatment of vascular malformations
EP1745800A1 (en) Novel blt2-mediated disease, and blt2 binding agent and compound
JP5196787B2 (ja) 増殖性疾患を治療するためのα，β−不飽和スルホキシド
AU2011232341B2 (en) Improved stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfone
WO2005085188A2 (en) Compounds and methods for anti-tumor therapy
WO2004106292A1 (en) Haloethyl urea compounds and their use to attenuate, inhibit or prevent non-cancerous pathogenic cellular proliferation and diseases associated therewith

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050131

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20050901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080502

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080502

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080502

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080603

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080729

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080811

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110815

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110815

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120815

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130815

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees